PDCD1 and cancer: Immunotherapy with several checkpoint blockers targeting programmed cell death protein 1 (PD-1), PD-1 ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) has resulted in significant improvements in the clinical outcomes of patients with various types of cancers including melanoma 6.